Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. headquartered in Nashville, and Tabuk Pharmaceutical Manufacturing Company, a fully owned subsidiary of Astra Industrial Group and a leading pharmaceutical company in the Middle East, headquartered in Riyadh, Saudi Arabia, today announced the launch of Cumberland’s Vibativ (telavancin) injection in the Middle East.
The announcement followed up with an agreement between the two firms offering Tabuk the exclusive rights to register and promote the product for patients in Saudi Arabia, Jordan, and potentially other countries in the Middle East.
According to healthcare industry sources in Tabuk Pharmaceuticals, and as per the firm’s claims, Vibativ serves as a potentially life-saving treatment in patients with hospital-acquired and ventilator-associated pneumonia resulting from a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and are multidrug-resistant.
The firm also stated that as a once-daily-dosed antibiotic, Vibativ does not require therapeutic drug monitoring, decreasing health care professionals’ exposure to the patient.
Mohammed Al Hagbani, president of Astra Industrial Group commented: “As part of our role and mission in Tabuk to deliver unique health solutions and save lives of people throughout the Middle East countries we operate in, we believe that Vibativ will provide our physicians with a powerful new tool to battle multidrug-resistant infections including MRSA, hospital-acquired pneumonia and ventilator-associated pneumonia.”
Wisam Alkhatib, vice president of strategy & business development at Tabuk Pharmaceuticals stated: “Vibativ is a life-saving product for certain difficult-to-treat infections and a key addition to Tabuk’s anti-infective portfolio, strengthening our leading market position in this therapy area and delivering on our strategy of building our specialty and innovative business while also reinforcing our leading position in the territory.”
A.J. Kazimi, CEO of Cumberland Pharmaceuticals commented: “Tabuk is a well-respected pharmaceutical company with a strong distribution network throughout the Middle East, and we are proud to partner with them to introduce Vibativ to this market. They have the resources and experience to ensure that Vibativ reaches as many patients within the territory as possible, and we look forward to a successful partnership.”
